Safety concerns about intravenous iron therapy in patients with chronic kidney disease

Clinical Kidney Journal

Volumn 9, Issue 2, 2016, Pages 260-267

  Del Vecchio, Lucia ^a   Longhi, Selena ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

anaphylaxis; atherosclerosis; chronic kidney disease; iron; safety

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; IRON; IRON SACCHARATE;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL GROWTH; CHRONIC KIDNEY DISEASE; DEATH; FERRITIN BLOOD LEVEL; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; IRON OVERLOAD; IRON THERAPY; MOLECULAR WEIGHT; MORTALITY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TISSUE INJURY; TREATMENT OUTCOME;

EID: 84963938772     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv142     Document Type: Review

References (86)

1. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
2. Stancu S, Barsan L, Stanciu A, et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol 2010; 5: 409-416
3. Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 55: 639-647
4. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
5. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335
6. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359
7. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013; 62: 849-859
8. Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013; 62: 860-873
9. http://www.nice.org.uk/guidance/ng8 (9 December 2015, date last accessed
10. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/news-detail-001833.jsp&mid=WC0b01ac058004d5c1 (26 January 2015, date last accessed
11. Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
12. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. Am Soc Nephrol 2004; 15: 1623-1632
13. Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845-854
14. Bailie GR, Larkina M, Goodkin DA, et al. Data fromthe Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168
15. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Timedependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
16. Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1930-1939
17. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864
18. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-Analysis. Am J Nephrol 2014; 39: 130-141
19. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB#F (15 April 2015, date last accessed
20. Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for US dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013; 62: 1213-1216
21. Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol 2015; 10: 1814-1821
22. Evans M, Suttorp MM, Bellocco R, et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant 2015; doi: 10.1093/ndt/gfv298
23. Kovesdy CP, Estrada W, Ahmadzadeh S, et al. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 435-441
24. Hatamizadeh P, Ravel V, Lukowsky LR, et al. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 2889-2898
25. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients? Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
26. Ali M, Rigolosi R, Fayemi AO, et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982; 1: 652-655
27. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. AmJ Kidney Dis 2010; 55: 726-741
28. Bárány P, Eriksson LC, Hultcrantz R, et al. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 1997; 23: 273-276
29. Brissot P, Ropert M, Le Lan C, et al. Non-Transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012; 1820: 403-410
30. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098
31. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysisassociated hemosiderosis in the era of erythropoiesisstimulating agents: a MRI study. Am J Med 2012; 125: 991-999
32. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-Term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012; 89: 87-93
33. Rostoker G, Griuncelli M, Loridon C, et al. Reassessment of iron biomarkers for prediction of dialysis iron overload: an MRI study. PLoS One 2015; 10: e0132006
34. Masuda Y, Ichii H, Vaziri ND. At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death. Am J Transl Res 2013; 6: 64-70
35. Alnahal AA, Tahan M, Fathy A, et al. Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. Saudi J Kidney Dis Transpl 2014; 25: 808-813
36. Fishbane S, Miyawaki N, Masani N. Hepatic iron in hemodialysis patients. Kidney Int 2004; 66: 1714-1715
37. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients. Semin Dial 2014; 27: 26-36
38. Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014; 29: 809-822
39. Ichii H, Masuda Y, Hassanzadeh T, et al. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50-57
40. Teehan GS, Bahdouch D, Ruthazer R, et al. Iron storage indices: novel predictors of bacteriemia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38: 1090-1094
41. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
42. Brewster UC, Coca SG, Reilly RF, et al. Effect of intravenous iron on hemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) 2005; 10: 124-128
43. Barton Pai A, Pai J, Depczynski CR, Mercier, RC. Non-Transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006; 26: 304-309
44. Teehan GS, Bahdouch D, Ruthazer R, et al. Iron storage indices: novel predictors of bacteriemia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38: 1090-1094
45. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
46. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-Analysis of randomised clinical trials. BMJ 2013; 347: f4822
47. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteriemia in chronic hamodialysis patients. Clin Nephrol 2002; 57: 457-461
48. Ganguli A, Kohli HS, Khullar M, et al. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail 2009; 31: 106-110
49. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219: 1-14
50. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-Term safety. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S19-S20
51. Bailie GR, Schuler C, Leggett RE, et al. Oxidative effect of several intravenous iron complexes in the rat. Biometals 2013; 26: 473-478
52. Kuo KL, Hung SC, Lee TS, et al. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014; 25: 2596-2606
53. Toblli JE, Cao G, Angerosa M. Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations. Int J Cardiol 2015; 187: 196-197
54. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004; 24: 949-954
55. Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol 2012; 59: 166-177
56. Stanley N, Stadler N, Woods AA, et al. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic Biol Med 2006; 40: 1636-1643
57. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis?. Circ Cardiovasc Genet 2009; 2: 652-657
58. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol 2012; 32: 1158-1166
59. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep 2013; 5: 1436-1442
60. Rajendran R, Minqin R, Ronald JA, et al. Does iron inhibit calcification during atherosclerosis?. Free Radic Biol Med 2012; 53: 1675-1679
61. Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
62. van derWeerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013; 28: 3062-3071
63. Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-Term risk of cardiovascular events in hemodialysis patients. PLoS One 2013; 8: e78930
64. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/news-detail-001833.jsp&mid=WC0b01ac058004d5c1 (26 January 2015, date last accessed
65. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014; 34: 707-723
66. Zinderman C, Landow L, Wise R. Anaphylactoid reactions to dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg 2006; 43: 1004-1009
67. Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 1994; 72: 224-228
68. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99: 1671-1676
69. Hamstra RD, Block MH, Schock, et al. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731
70. Fletes R, Lazarus JM, Gage J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37: 743-749
71. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep?s clothing?. J Am Soc Nephrol 2008; 19: 833-834
72. Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-1575
73. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfus Altern Transfus Med 2007; 1: 1-7
74. Sav T, Tokgoz B, Sipahioglu MH. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail 2007; 29: 423-426
75. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-Type reactions. Am J Hematol 2010; 85: 650-654
76. http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm (15 April 2015, date last accessed
77. Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449
78. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-Analysis. Mayo Clin Proc 2015; 90: 12-23
79. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314: 2062-2068
80. Rivera R, Guido D, Del Vecchio L, et al. The Lombardy Section of Italian Society of Nephrology. Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. J Nephrol 2015; in press
81. Chung M, Moorthy D, Hadar N, et al. Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease. Report no. 12(13)-EHC140-EF. Rockville, MD: Agency for Healthcare Research and Quality (US), 2012
82. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463
83. Mercadel L, Metzger M, Haymann JP, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014; 9: e99781
84. Bârsan L, Stanciu A, Stancu S, et al. Bone marrowiron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology 2015; 20: 543-552
85. Costa E, Swinkels DW, Laarakkers CM, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009; 122: 226-229
86. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematol Am Soc Hematol Educ Program 2009: 215-221